276 related articles for article (PubMed ID: 35534786)
1. Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study.
Bello N; Birt JA; Workman J; Zhou X; Ross-Terres JA; Petri M
Adv Ther; 2022 Jul; 39(7):3131-3145. PubMed ID: 35534786
[TBL] [Abstract][Full Text] [Related]
2. Treatment pathways in an inception lupus cohort over the first three years.
Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
[TBL] [Abstract][Full Text] [Related]
3. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort.
Watson P; Brennan A; Birch H; Fang H; Petri M
Rheumatology (Oxford); 2015 Apr; 54(4):623-32. PubMed ID: 25234659
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Wang L; Yang Y; Jia Y; Miao H; Zhou YS; Zhang XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1081-1085. PubMed ID: 27987518
[TBL] [Abstract][Full Text] [Related]
5. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.
Ribi C; Trendelenburg M; Gayet-Ageron A; Cohen C; Dayer E; Eisenberger U; Hauser T; Hunziker T; Leimgruber A; Lindner G; Koenig K; Otto P; Spertini F; Stoll T; Von Kempis J; Chizzolini C;
Swiss Med Wkly; 2014; 144():w13990. PubMed ID: 25115978
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB
Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
[TBL] [Abstract][Full Text] [Related]
8. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
10. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
van Vollenhoven R; Voskuyl A; Bertsias G; Aranow C; Aringer M; Arnaud L; Askanase A; Balážová P; Bonfa E; Bootsma H; Boumpas D; Bruce I; Cervera R; Clarke A; Coney C; Costedoat-Chalumeau N; Czirják L; Derksen R; Doria A; Dörner T; Fischer-Betz R; Fritsch-Stork R; Gordon C; Graninger W; Györi N; Houssiau F; Isenberg D; Jacobsen S; Jayne D; Kuhn A; Le Guern V; Lerstrøm K; Levy R; Machado-Ribeiro F; Mariette X; Missaykeh J; Morand E; Mosca M; Inanc M; Navarra S; Neumann I; Olesinska M; Petri M; Rahman A; Rekvig OP; Rovensky J; Shoenfeld Y; Smolen J; Tincani A; Urowitz M; van Leeuw B; Vasconcelos C; Voss A; Werth VP; Zakharova H; Zoma A; Schneider M; Ward M
Ann Rheum Dis; 2017 Mar; 76(3):554-561. PubMed ID: 27884822
[TBL] [Abstract][Full Text] [Related]
11. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.
Hill DD; Eudy AM; Egger PJ; Fu Q; Petri MA
Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33832976
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
Kalunian KC; Urowitz MB; Isenberg D; Merrill JT; Petri M; Furie RA; Morgan-Cox MA; Taha R; Watts S; Silk M; Linnik MD
Rheumatology (Oxford); 2018 Jan; 57(1):125-133. PubMed ID: 29045736
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy for systemic lupus erythematosus.
Taylor JK; McMurray RV
J Miss State Med Assoc; 2011 Feb; 52(2):39-43. PubMed ID: 21387869
[TBL] [Abstract][Full Text] [Related]
14. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study.
Cortés-Hernández J; Marras Fernández-Cid C; Andreu Sánchez JL; Calvo Alén J; García-Aparicio AM; Díez Álvarez E; Hidalgo Bermejo FJ; Coronell C; Perna A; Ordi Ros J
Reumatol Clin (Engl Ed); 2023; 19(6):312-318. PubMed ID: 37286267
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
[TBL] [Abstract][Full Text] [Related]
16. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
Joo YB; Bae SC
Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
[TBL] [Abstract][Full Text] [Related]
17. Patterns of disease activity in systemic lupus erythematosus.
Barr SG; Zonana-Nacach A; Magder LS; Petri M
Arthritis Rheum; 1999 Dec; 42(12):2682-8. PubMed ID: 10616018
[TBL] [Abstract][Full Text] [Related]
18. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?
Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA;
Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653
[TBL] [Abstract][Full Text] [Related]
19. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
Thanou A; Chakravarty E; James JA; Merrill JT
Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
[TBL] [Abstract][Full Text] [Related]
20. Systemic lupus erythematosus.
Madhok R; Wu O
BMJ Clin Evid; 2009 Jul; 2009():. PubMed ID: 21696649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
